KRAS/NRAS/BRAF mutations were mutually exclusive, and the highest mutation prevalence in RAS pathway was observed in ECC (49.1%) vs. ICC (27.1%) and GBC (19.2%). This evidence concerns the gene KRAS and intrahepatic cholangiocarcinoma.